ATE58835T1 - Sterilisierte plasmanebenprodukte und verfahren zur herstellung. - Google Patents

Sterilisierte plasmanebenprodukte und verfahren zur herstellung.

Info

Publication number
ATE58835T1
ATE58835T1 AT83103049T AT83103049T ATE58835T1 AT E58835 T1 ATE58835 T1 AT E58835T1 AT 83103049 T AT83103049 T AT 83103049T AT 83103049 T AT83103049 T AT 83103049T AT E58835 T1 ATE58835 T1 AT E58835T1
Authority
AT
Austria
Prior art keywords
factor viii
plasma
manufacture
methods
sterilized
Prior art date
Application number
AT83103049T
Other languages
English (en)
Inventor
Alfred Mayer Prince
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23450479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE58835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Application granted granted Critical
Publication of ATE58835T1 publication Critical patent/ATE58835T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Lubricants (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT83103049T 1982-04-14 1983-03-26 Sterilisierte plasmanebenprodukte und verfahren zur herstellung. ATE58835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/368,250 US4481189A (en) 1982-04-14 1982-04-14 Process for preparing sterilized plasma and plasma derivatives
EP83103049A EP0099445B2 (de) 1982-04-14 1983-03-26 Sterilisierte Plasmanebenprodukte und Verfahren zur Herstellung

Publications (1)

Publication Number Publication Date
ATE58835T1 true ATE58835T1 (de) 1990-12-15

Family

ID=23450479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83103049T ATE58835T1 (de) 1982-04-14 1983-03-26 Sterilisierte plasmanebenprodukte und verfahren zur herstellung.

Country Status (13)

Country Link
US (1) US4481189A (de)
EP (1) EP0099445B2 (de)
JP (1) JPH0660105B2 (de)
AT (1) ATE58835T1 (de)
AU (1) AU561900B2 (de)
CA (1) CA1207229A (de)
DE (1) DE3382042D1 (de)
DK (1) DK164537C (de)
ES (1) ES521431A0 (de)
FI (1) FI80211C (de)
NO (1) NO163514C (de)
NZ (1) NZ203878A (de)
ZA (1) ZA832239B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581231A (en) * 1982-06-10 1986-04-08 The United States Of America As Represented By The Secretary Of Health And Human Services Inactivation of viruses containing essential lipids
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
CA1254839A (en) * 1984-08-14 1989-05-30 Mark W. Torrianni Retarded mineralization of implantable tissue by surface active betaines
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
US4971760A (en) * 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells
US5211912A (en) * 1986-08-01 1993-05-18 University Of Southern California Method for disinfecting red blood cells, blood products, and corneas
AT390374B (de) * 1986-03-18 1990-04-25 Schwab & Co Gmbh Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US4944920A (en) * 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
AU6942387A (en) * 1986-08-01 1988-03-24 Rubinstein, A.I. A method to treat blood
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US4869826A (en) * 1987-09-01 1989-09-26 Process Biotechnology, Inc. Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions
DE3733181C1 (de) * 1987-10-01 1989-01-19 Biotest Pharma Gmbh Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
DE3805459A1 (de) * 1988-02-22 1989-08-31 Biotest Pharma Gmbh Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
DE3826792C1 (de) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
JPH09500015A (ja) * 1993-06-23 1997-01-07 ニューヨーク ブラッド センター，インコーポレイティド 血液のウィルス不活性化のためのシステム
USRE37584E1 (en) 1993-07-30 2002-03-19 Aruba International Pty Ltd Solvent extraction methods for delipidating plasma
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
FR2716111B1 (fr) * 1994-02-11 1996-11-08 Cogia Procédé de préparation d'une composition cosmétique ou alimentaire apte à être conservée, dispositif et composition de longue conservation.
US5486293A (en) * 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
DE69512416T3 (de) † 1994-07-14 2011-12-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
FI952196A0 (fi) * 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
WO1996037242A1 (en) * 1995-05-26 1996-11-28 Naficy Sadeque S Apparatuses and methods for treatment of blood
DE19528221C2 (de) * 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
US6436344B1 (en) * 1999-11-02 2002-08-20 American National Red Cross Method of inactivating pathogens
KR20020063597A (ko) * 1999-12-20 2002-08-03 미츠비시 웰파마 가부시키가이샤 다공성막으로 처리되어 바이러스가 제거된 혈장 단백질조성물 및 그 제조 방법
WO2001045749A1 (en) * 1999-12-22 2001-06-28 The Trustees Of The University Of Pennsylvania Cosmid dna constructs and methods of making and using the same
AUPQ486699A0 (en) * 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
RU2188654C1 (ru) * 2001-12-13 2002-09-10 Государственное некоммерческое учреждение Гематологический научный центр РАМН Препараты крови для трансфузии и способ их получения
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
US8986607B2 (en) * 2003-02-27 2015-03-24 Baxter International Inc. Method for the validatable inactivation of pathogens in a biological fluid by irradiation
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses
EP1765866B1 (de) 2004-06-07 2014-01-08 Therapure Biopharma Inc. Isolierung von plasma- oder serumprotein
US7993580B2 (en) * 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
EP1685852A1 (de) 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set von Einwegbeuteln zur Virusinaktivierung von biologischen Fluids
ES2775974T3 (es) * 2006-06-26 2020-07-28 Omrix Biopharmaceuticals Inc Eliminación de virus por nanofiltración
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
BRPI0909724A2 (pt) * 2008-03-28 2017-06-13 Res Foundation For Medical Devices método de inativação viral de fluidos biológicos por tratamento com solvente/detergente.
EP2385825B1 (de) 2008-11-07 2018-10-10 University of Connecticut Faktor-viii-formulierungen
EP2399613A1 (de) 2010-06-22 2011-12-28 Research Foundation For Medical Devices Plasmafraktionierung mittels Verwendung der Caprylsäure
CN106138851A (zh) * 2016-09-08 2016-11-23 四川聚豪生物科技有限公司 一种可有效治疗乙肝的汤剂药物及其制备方法
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
WO2019104237A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (de) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. Verfahren zur konservierung und verabreichung von aus menschlichem plasma extrahiertem prä-beta-lipoprotein hoher dichte
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
CA3150936A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
US20210069240A1 (en) * 2019-09-05 2021-03-11 Cellphire, Inc. Materials and methods for blood plasma preparations
CA3170198A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
US20220273724A1 (en) 2021-02-17 2022-09-01 Cellphire Inc. Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
GB1507215A (en) * 1975-08-19 1978-04-12 Green Cross Corp Processes for producing immunoregulatory preparations
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4222934A (en) * 1979-04-12 1980-09-16 American National Red Cross Preparation of albumin using ethanol
EP0035204B2 (de) * 1980-03-05 1991-05-22 Miles Inc. Pasteurisierte therapeutisch aktive Proteinzusammensetzungen
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
DE3033932C2 (de) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
EP0050061B2 (de) * 1980-10-06 1990-06-20 New York Blood Center, Inc. Verfahren zum Vermindern unerwünschter Wirkungen biologischer und pharmazeutischer Produkte

Also Published As

Publication number Publication date
DK164537B (da) 1992-07-13
FI831146A0 (fi) 1983-04-05
ES8403722A1 (es) 1984-04-01
DK162983A (da) 1983-10-15
FI80211C (fi) 1990-05-10
EP0099445B2 (de) 1998-07-08
CA1207229A (en) 1986-07-08
JPH0660105B2 (ja) 1994-08-10
NZ203878A (en) 1986-02-21
ZA832239B (en) 1984-11-28
NO163514B (no) 1990-03-05
AU561900B2 (en) 1987-05-21
NO163514C (no) 1990-06-13
AU1346283A (en) 1983-10-20
EP0099445A2 (de) 1984-02-01
FI80211B (fi) 1990-01-31
DE3382042D1 (de) 1991-01-17
DK164537C (da) 1992-11-30
NO831304L (no) 1983-10-17
US4481189A (en) 1984-11-06
JPS58222023A (ja) 1983-12-23
ES521431A0 (es) 1984-04-01
EP0099445A3 (en) 1985-01-16
FI831146L (fi) 1983-10-15
EP0099445B1 (de) 1990-12-05
DK162983D0 (da) 1983-04-13

Similar Documents

Publication Publication Date Title
DE3382042D1 (de) Sterilisierte plasmanebenprodukte und verfahren zur herstellung.
US4841023A (en) Inactivation of viruses in labile protein-containing compositions using fatty acids
EP0131740B1 (de) Nichtdenaturierte virusfreie biologisch aktive Proteinderivate
US4613501A (en) Inactivation of viruses in labile blood derivatives
US4764369A (en) Undenatured virus-free biologically active protein derivatives
ES2101077T3 (es) Procedimiento para la inactivacion de priones.
ATA123791A (de) Verfahren zur herstellung eines inaktivierten blutproduktes
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69739268D1 (de) Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
ES2174957T3 (es) Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
Horowitz et al. Viral safety of solvent/detergent-treated blood products
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
US4820805A (en) Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
DE68923169D1 (de) Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE59506747D1 (de) Verfahren zur herstellung eines virussicheren, therapeutischen, biologischen präparates
Morgenthaler Virus inactivation in plasma products
Lane et al. THE NEW YORK BLOOD CENTER
Gerety Prevention of transmission of virus infections by blood transfusions and removal of virus infectivity from clotting factor concentrates
Um et al. Infectious Disease Markers among Directed and Volunteer Blood Donors in Korea

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time